L
Liyang Zhang
Researcher at Central South University
Publications - 11
Citations - 376
Liyang Zhang is an academic researcher from Central South University. The author has contributed to research in topics: Glioma & Immune checkpoint. The author has an hindex of 6, co-authored 11 publications receiving 95 citations. Previous affiliations of Liyang Zhang include University of Oklahoma Health Sciences Center.
Papers
More filters
Journal ArticleDOI
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Hao Zhang,Ziyu Dai,Wantao Wu,Zeyu Wang,Nan Zhang,Liyang Zhang,Wen-Jing Zeng,Zhixiong Liu,Quan Cheng +8 more
TL;DR: In this article, the authors discussed the regulation of PD-L1 and CTLA-4 at the levels of DNA, RNA, and proteins, as well as indirect regulation of biomarkers, localization within the cell, and drugs.
Journal ArticleDOI
The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
Hao Zhang,Yue-Bei Luo,Wantao Wu,Liyang Zhang,Zeyu Wang,Ziyu Dai,Songshan Feng,Hui Cao,Quan Cheng,Zhixiong Liu +9 more
TL;DR: Wang et al. as discussed by the authors used weighted gene co-expression network analysis to identify meaningful macrophage-related gene genes for clustering and applied Pamr, SVM, and neural network for validating clustering results.
Journal ArticleDOI
Screening for distress in patients with primary brain tumor using distress thermometer: a systematic review and meta-analysis.
TL;DR: Routine screening and evaluation of distress in brain tumor patients may assist medical workers to develop proper interventions, which may lead to better quality of life and oncology management.
Journal ArticleDOI
PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
Hao Zhang,Jialin He,Ziyu Dai,Zeyu Wang,Xisong Liang,Fengqiong He,Zhiwei Xia,Songshan Feng,Hui Cao,Liyang Zhang,Quan Cheng +10 more
TL;DR: Zhang et al. as mentioned in this paper found that PDIA5 expression level is upregulated in aggressive gliomas, with high PDIA-5 expression predicting poor clinical outcomes. And they also observed a positive correlation between PDI5 and immune infiltrating cells, immune related pathways, inflammatory activities, and other immune checkpoint members.
Journal ArticleDOI
CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
TL;DR: Findings show that CD96 is promising candidate for immunotherapy, and that such agents could complement current immunotherapy strategies for glioma.